Symptom-free and rescue-free 24 h periods over weeks 1–8 (intent-to-treat population)
| Placebo | FF | FP | ||||
| (n=103) | 200 μg OD (n=99) | 400 μg OD (n=101) | 600 μg OD (n=107) | 800 μg OD (n=102) | 500 μg BD (n=110) | |
| Symptom-free 24 h periods | ||||||
| n | 101 | 99 | 101 | 107 | 101 | 110 |
| LS mean change (SE) | 6.4 (2.71) | 20.1 (2.74) | 19.6 (2.71) | 15.1 (2.63) | 18.5 (2.71) | 15.4 (2.61) |
| Difference versus placebo | ||||||
| LS mean difference 95% CI | 13.7 (6.1 to 21.3) | 13.2 (5.7 to 20.8) | 8.7 (1.3 to 16.1) | 12.1 (4.6 to 19.7) | 9.1 (1.7 to 16.5) | |
| p Value | <0.001 | <0.001 | 0.022 | 0.002 | 0.017 | |
| Rescue-free 24 h periods | ||||||
| N | 101 | 99 | 101 | 107 | 101 | 110 |
| LS mean change (SE) | 3.6 (2.75) | 17.9 (2.78) | 21.2 (2.75) | 17.4 (2.67) | 22.3 (2.75) | 16.7 (2.63) |
| Difference versus placebo | ||||||
| LS mean difference 95% CI | 14.4 (6.7 to 22.0) | 17.6 (10.0 to 25.3) | 13.8 (6.3 to 21.4) | 18.7 (11.1 to 26.3) | 13.2 (5.7 to 20.6) | |
| p Value | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | |
BD, twice daily; FF, fluticasone furoate; FP, fluticasone propionate; LS, least squares; OD, once daily.